Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a price target of $16.
October 08, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Black Diamond Therapeutic and maintained a $16 price target, indicating confidence in the company's potential for growth.
The reiteration of an Outperform rating and maintenance of a $16 price target by a reputable analyst suggests positive sentiment and potential upside for BDTX. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100